Gan&Lee Pharmaceuticals.(603087),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

603087 Gan&Lee Pharmaceuticals.

Closed 07-17 15:00:00

64.27

-5.13

-7.39%

High68.99	Low64.18	Vol18.50M
Open68.03	D1 Closing69.40	Amplitude6.93%
Mkt Cap38.37B	Tradable Cap36.06B	Total Shares597.00M
T/O1.22B	T/O Rate3.30%	Tradable Shares561.00M
P/B3.25	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"603087","market":"SH","secType":"STK","nameCN":"Gan&Lee Pharmaceuticals.","latestPrice":64.27,"timestamp":1784271601000,"preClose":69.4,"halted":0,"volume":18498597,"delay":0,"changeRate":-0.0739,"floatShares":561000000,"shares":597000000,"eps":1.7147,"marketStatus":"Closed","change":-5.13,"latestTime":"07-17 15:00:00","open":68.03,"high":68.99,"low":64.18,"amount":1222000000,"amplitude":0.0693,"askPrice":64.27,"askSize":412,"bidPrice":64.26,"bidSize":232,"shortable":0,"etf":0,"ttmEps":1.7147,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1784511000000},"marketStatusCode":5,"adr":0,"adjPreClose":69.4,"symbolType":"stock","openAndCloseTimeList":[[1784251800000,1784259000000],[1784264400000,1784271600000]],"highLimit":76.34,"lowLimit":62.46,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":597304969,"isCdr":false,"pbRate":3.25,"roa":"--","peRate":37.481775,"roe":"1.64%","epsLYR":1.93,"committee":-0.412863,"marketValue":38389000000,"turnoverRate":0.033,"status":1,"nextConnectDate":"Northbound have stopped. The next trading day is UTC+8 2026-07-20.","floatMarketCap":36066000000},"requestUrl":"/m/hq/s/603087/wiki","defaultTab":"wiki","newsList":[{"id":"2651194518","title":"Gan & Lee Pharmaceuticals Gets China Nod for Breast Cancer Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2651194518","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651194518?lang=en_us&edition=fundamental","pubTime":"2026-07-13 16:21","pubTimestamp":1783930900,"startTime":"0","endTime":"0","summary":"Gan & Lee Pharmaceuticals  received clinical trial approval from China's drug regulator for GLR2038 tablets to treat advanced breast cancer.The drug, developed on the company's proprietary PROTAC platform, will proceed to monotherapy trials, according to a weekend filing with the Shanghai bourse.Shares of the pharmaceutical company rose 6% Monday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650025099","title":"Gan & Lee Pharmaceuticals Secures Honduras Approval for Diabetes Drug; Shares Up 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650025099","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650025099?lang=en_us&edition=fundamental","pubTime":"2026-07-10 14:16","pubTimestamp":1783664180,"startTime":"0","endTime":"0","summary":"Gan & Lee Pharmaceuticals  received drug registration approval in Honduras for its insulin glargine injection, Vitaglar.The drug is a long-acting basal insulin for the treatment of diabetes, according to a Friday filing with the Shanghai bourse.Shares of the pharmaceutical company rose 6% in recent trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162731774","title":"Gan&Lee Pharmaceuticals Secures Honduran Regulatory Approval for Its Insulin Glargine Prefilled Pen","url":"https://stock-news.laohu8.com/highlight/detail?id=1162731774","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162731774?lang=en_us&edition=fundamental","pubTime":"2026-07-09 17:50","pubTimestamp":1783590629,"startTime":"0","endTime":"0","summary":"Gan&Lee Pharmaceuticals. (ASX: 603087) has announced that it has received a drug registration approval from the Honduran National Drug Administration for its insulin glargine injection (prefilled...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647437553","title":"Gan & Lee Pharmaceuticals Gets Honduras Approval for Insulin Jab","url":"https://stock-news.laohu8.com/highlight/detail?id=2647437553","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647437553?lang=en_us&edition=fundamental","pubTime":"2026-06-29 18:54","pubTimestamp":1782730460,"startTime":"0","endTime":"0","summary":"Honduran authorities approved Gan & Lee Pharmaceuticals' (SHA:603087) insulin glargine injection for diabetes, according to a Monday filing with the Shanghai bourse.The drug is said to have a hypoglycemic effect lasting 24 hours, the company said in its filing.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142698666","title":"Gan & Lee Pharmaceuticals Secures Registration Approval for Insulin Glargine Injection in Honduras","url":"https://stock-news.laohu8.com/highlight/detail?id=1142698666","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142698666?lang=en_us&edition=fundamental","pubTime":"2026-06-26 18:16","pubTimestamp":1782469012,"startTime":"0","endTime":"0","summary":"Gan & Lee Pharmaceuticals. (SHSE: 603087) has announced that it recently received a drug registration approval for its Insulin Glargine Injection from the National Pharmaceutical Regulatory Authority...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152271526","title":"Gan & Lee Pharmaceuticals Seizes a Niche Opportunity in the Insulin Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1152271526","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152271526?lang=en_us&edition=fundamental","pubTime":"2026-06-23 22:21","pubTimestamp":1782224477,"startTime":"0","endTime":"0","summary":"The recent market rotation has seen the spotlight shift from AI to the pharmaceutical sector, with innovative drug stocks capturing investor attention. Some have quipped that healthcare stocks only...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134844537","title":"Gan & Lee Pharmaceuticals Secures UAE Drug Registration for Insulin Glargine Pre-filled Pen","url":"https://stock-news.laohu8.com/highlight/detail?id=1134844537","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134844537?lang=en_us&edition=fundamental","pubTime":"2026-06-18 17:04","pubTimestamp":1781773475,"startTime":"0","endTime":"0","summary":"Gan & Lee Pharmaceuticals Co., Ltd. (SHSE: 603087) has announced that its wholly-owned European subsidiary, Gan & Lee Pharmaceuticals Europe GmbH, has recently received a drug registration approval...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642600902","title":"Gan & Lee Pharmaceuticals - Once-Weekly Insulin Ludefen Shows Favorable Safety Profile With No Severe Hypoglycemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2642600902","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642600902?lang=en_us&edition=fundamental","pubTime":"2026-06-12 20:01","pubTimestamp":1781265672,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nFWN42J154:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642260099","title":"Gan & Lee Pharmaceuticals - Insulin Ludefen (Gzr4) Meets Primary Endpoint in Phase Iii Trial in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2642260099","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642260099?lang=en_us&edition=fundamental","pubTime":"2026-06-12 20:01","pubTimestamp":1781265672,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nFWN42J154:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102374961","title":"Gan & Lee Pharmaceuticals Unveils Restricted Stock Incentive Plan for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1102374961","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102374961?lang=en_us&edition=fundamental","pubTime":"2026-06-10 20:28","pubTimestamp":1781094500,"startTime":"0","endTime":"0","summary":"Gan & Lee Pharmaceuticals. (ASX: 603087) has announced a draft proposal for a 2026 restricted stock incentive plan.The plan proposes to grant a total of 630,000 restricted shares to the incentive...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123200243","title":"Gan & Lee Pharmaceuticals Subsidiary Secures ANVISA Sterile Preparation GMP Certification in Brazil","url":"https://stock-news.laohu8.com/highlight/detail?id=1123200243","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123200243?lang=en_us&edition=fundamental","pubTime":"2026-05-26 17:20","pubTimestamp":1779787221,"startTime":"0","endTime":"0","summary":"Gan & Lee Pharmaceuticals (603087.SH) has announced that its subsidiary, Gan & Lee Pharmaceuticals Brazil Trading and Pharmaceutical Import Co., Ltd., recently received a Good Manufacturing Practice...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["603087","159100","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199496588","title":"Gan & Lee Pharmaceuticals Receives European Commission Approval for Insulin Lispro Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1199496588","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199496588?lang=en_us&edition=fundamental","pubTime":"2026-05-14 16:34","pubTimestamp":1778747669,"startTime":"0","endTime":"0","summary":"Gan & Lee Pharmaceuticals (603087.SH) announced that the company and its European wholly-owned subsidiary, Gan & Lee Pharmaceuticals Europe GmbH, have recently received notification from the European...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPOS","603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633411372","title":"Gan & Lee Pharmaceuticals Gets Nod to Market Dazparda in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2633411372","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633411372?lang=en_us&edition=fundamental","pubTime":"2026-05-07 16:04","pubTimestamp":1778141042,"startTime":"0","endTime":"0","summary":"The European Commission granted Gan & Lee Pharmaceuticals  marketing authorization for insulin aspart injection Dazparda, according to a Shanghai bourse filing on Thursday.The Chinese pharmaceutical company's unit, Gan & Lee Pharmaceuticals Europe, is the authorized marketer of the product in Europe.The company's shares rose 1% at the close.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140498045","title":"Gan & Lee Pharmaceuticals Receives European Commission Approval for Insulin Aspart Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1140498045","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140498045?lang=en_us&edition=fundamental","pubTime":"2026-05-06 17:35","pubTimestamp":1778060135,"startTime":"0","endTime":"0","summary":"Gan & Lee Pharmaceuticals (603087.SH) announced that the company and its European subsidiary, Gan & Lee Pharmaceuticals Europe GmbH, have received notification from the European Commission. The...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPOS","603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629001561","title":"BUZZ-China's Gan & Lee Pharmaceuticals heads for biggest drop in a year on lower Q1 results","url":"https://stock-news.laohu8.com/highlight/detail?id=2629001561","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629001561?lang=en_us&edition=fundamental","pubTime":"2026-04-23 13:16","pubTimestamp":1776921381,"startTime":"0","endTime":"0","summary":"BUZZ-China's Gan & Lee Pharmaceuticals heads for biggest drop in a year on lower Q1 results   ** Shares of Gan & Lee Pharmaceuticals 603087.SS drop 8.8% to 59.9 yuan, on track for biggest one-day pct decline since April 7, 2025** Stock hits the lowest level since March 27** China-based insulin analogue active pharmaceutical ingredients and injectable formulations producer said its Q1 net profit plunged 38.3% y/y with revenue down 10.8% y/y** YTD, stock down 12%, benchmark CSI300 Index .CSI300 up 2.9%  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nL1N41606K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629017531","title":"BRIEF-Gan & Lee Pharmaceuticals 2025 Net Profit Up 86.1% Y/Y","url":"https://stock-news.laohu8.com/highlight/detail?id=2629017531","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629017531?lang=en_us&edition=fundamental","pubTime":"2026-04-22 18:28","pubTimestamp":1776853686,"startTime":"0","endTime":"0","summary":"BRIEF-Gan & Lee Pharmaceuticals 2025 Net Profit Up 86.1% Y/YApril 22 (Reuters) - Gan & Lee Pharmaceuticals 603087.SS:2025 NET PROFIT UP 86.1% Y/YSource textFurther company coverage: 603087.SS (Reporting by Beijing Newsroom) ((Shi.Bu@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nL4N4150YT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627226679","title":"Gan & Lee Pharmaceuticals Gets Nod to Trial GLR1062 Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2627226679","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627226679?lang=en_us&edition=fundamental","pubTime":"2026-04-16 13:34","pubTimestamp":1776317640,"startTime":"0","endTime":"0","summary":"Gan & Lee Pharmaceuticals  received approval from China's National Medical Products Administration for the clinical trials of GLR1062 injection, according to a Shanghai bourse filing on Thursday.The drug will be tested for the treatment of neovascular  age-related macular degeneration in adults.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627406836","title":"Gan & Lee Pharmaceuticals' Subsidiary Doses First Subject for Phase III of GZR33 Injection Trial; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627406836","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627406836?lang=en_us&edition=fundamental","pubTime":"2026-04-15 14:49","pubTimestamp":1776235795,"startTime":"0","endTime":"0","summary":"Gan & Lee Pharmaceuticals'  subsidiary, Gan & Lee Pharmaceuticals Shandong, dosed the first subject for the phase III clinical trial of GZR33 injection, according to a Shanghai bourse filing on Wednesday.The drug is being tested as a treatment for type 2 diabetes.The pharmaceutical company's shares rose less than 3% during the afternoon trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["603087","III","BK4134","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626808251","title":"BRIEF-Gan & Lee Pharmaceuticals - Signs Exclusive License Agreement With Jw Pharmaceutical","url":"https://stock-news.laohu8.com/highlight/detail?id=2626808251","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626808251?lang=en_us&edition=fundamental","pubTime":"2026-04-09 21:13","pubTimestamp":1775740428,"startTime":"0","endTime":"0","summary":"BRIEF-Gan & Lee Pharmaceuticals - Signs Exclusive License Agreement With Jw PharmaceuticalApril 9 (Reuters) - Gan & Lee Pharmaceuticals 603087.SS:GAN & LEE PHARMACEUTICALS - SIGNS EXCLUSIVE LICENSE AG","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nFWN40S0DB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626187061","title":"Gan & Lee Pharmaceuticals - Parties to Collaborate, Others on Clinical Development in South Korea of Bofanglutide Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2626187061","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626187061?lang=en_us&edition=fundamental","pubTime":"2026-04-09 21:10","pubTimestamp":1775740213,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nFWN40S0DB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1784311398529,"stockEarnings":[{"period":"1week","weight":-0.0331},{"period":"1month","weight":0.1884},{"period":"3month","weight":0.0054},{"period":"6month","weight":-0.0879},{"period":"1year","weight":0.1171},{"period":"ytd","weight":-0.0377}],"compareEarnings":[{"period":"1week","weight":-0.0581},{"period":"1month","weight":-0.0837},{"period":"3month","weight":-0.0709},{"period":"6month","weight":-0.0823},{"period":"1year","weight":0.0703},{"period":"ytd","weight":-0.0516}],"compareStock":{"symbol":"000001.SH","name":"SSE Comp"},"companyName":"甘李药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"81965人(较上一季度减少5.45%)","perCapita":"6846股","listingDate":"2020-06-29","address":"北京市通州区漷县镇南凤西一路8号","registeredCapital":"59730万元","survey":"　　甘李药业股份有限公司的主营业务是胰岛素类似物原料药及注射剂研发、生产和销售。公司的主要产品是甘精胰岛素注射液、赖脯胰岛素注射液、精蛋白锌重组赖脯胰岛素混合注射液、门冬胰岛素注射液、门冬胰岛素30注射液、精蛋白人胰岛素混合注射液。","listedPrice":63.32},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Gan&Lee Pharmaceuticals.(603087),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Gan&Lee Pharmaceuticals.(603087) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Gan&Lee Pharmaceuticals.,603087,Gan&Lee Pharmaceuticals.股票,Gan&Lee Pharmaceuticals.股票老虎,Gan&Lee Pharmaceuticals.股票老虎国际,Gan&Lee Pharmaceuticals.行情,Gan&Lee Pharmaceuticals.股票行情,Gan&Lee Pharmaceuticals.股价,Gan&Lee Pharmaceuticals.股市,Gan&Lee Pharmaceuticals.股票价格,Gan&Lee Pharmaceuticals.股票交易,Gan&Lee Pharmaceuticals.股票购买,Gan&Lee Pharmaceuticals.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Gan&Lee Pharmaceuticals.(603087),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Gan&Lee Pharmaceuticals.(603087) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction